Related Experiment Video

Updated: Jun 8, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Individualization of treatment in non-small cell lung cancer

Nico van Zandwijk1

  • 1Bernie Banton Centre, University of Sydney Hospital Road, Concord, 2139 NSW Australia.

F1000 Medicine Reports
|October 16, 2010
PubMed

Insights

Accurate subclassification of non-small cell lung cancer (NSCLC) is becoming essential for personalized chemotherapy and targeted therapies. This marks a shift away from treating all NSCLC subtypes uniformly.

Area of Science:

  • Oncology
  • Medical Genetics

Background:

  • Non-small cell lung cancer (NSCLC) treatment has historically used broad classifications.
  • Recent advancements necessitate a more granular approach to NSCLC subtyping.

Purpose of the Study:

  • To highlight the importance of accurate NSCLC subclassification for personalized medicine.
  • To discuss the implications of recent randomized studies on NSCLC treatment strategies.

Main Methods:

  • Review of two recently reported randomized clinical studies.
  • Analysis of treatment protocols for chemotherapy doublets and tyrosine kinase inhibitors.

Main Results:

  • Accurate NSCLC subclassification is crucial for selecting appropriate chemotherapy doublets.
  • Subtyping is essential for prescribing epidermal growth factor receptor tyrosine kinase inhibitors.
  • Current broad classification practices for NSCLC are becoming obsolete.

Conclusions:

  • Personalized treatment approaches for NSCLC are emerging.
  • The future of NSCLC treatment requires precise subclassification for optimal patient outcomes.

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...